Coeptis Therapeutics to Present Poster Data at ASGCT 27th Annual Meeting

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical firm headquartered in Wexford, Pennsylvania, has announced that their research on the SNAP-CAR NK cell platform will be showcased at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The event will take place both virtually and in-person from May 7-11, 2024, in Baltimore, Maryland. Representing Coeptis, Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Therapeutics, will present the data on this innovative platform.

SNAP-CAR NK cells are designed to target multiple antigens, presenting a potential therapeutic approach for a diverse array of cancers. The platform's development marks a significant leap forward in Coeptis' mission to create advanced cell therapy solutions for cancer, autoimmune, and infectious diseases. Dave Mehalick, President and CEO of Coeptis, emphasized the groundbreaking potential of combining scalable cell generation technology with SNAP-CAR's universal targeting capabilities. This integration aims to create cell therapies that are universally applicable and do not require HLA matching, potentially revolutionizing cancer treatment approaches.

The presentation, scheduled for May 9, 2024, at 12:00 PM, will be part of a session titled "Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies" in the Exhibit Hall. The abstract number for the presentation is 1325.

Coeptis Therapeutics Holdings, Inc. focuses on developing cell therapy platforms that could significantly alter traditional treatment methodologies and enhance patient outcomes. Among their notable assets are the allogeneic cellular immunotherapy platform and DVX201, a natural killer cell therapy technology in clinical stages, both licensed from Deverra Therapeutics. Additionally, Coeptis is working on a universal, multi-antigen CAR T technology (SNAP-CAR) licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and researchers at the Karolinska Institutet.

Coeptis' strategy revolves around maximizing the value of its product portfolio through various licensing and co-development agreements and strategic partnerships. This approach aims to expand their offerings, particularly in the realms of cancer and infectious diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!